Table 1 Effects of melatonin on ovary transplantation
From: Melatonin influence in ovary transplantation: systematic review
Author | Species | Study model | Melatonin route and dosage | Results of melatonin use |
|---|---|---|---|---|
Friedman, 2012 [3] | Human; Nu/nu Balb/c mice | Xenotransplanted thawed graft; donor: 5 cancer patients aged 6–23 years; recipient: 79 immunodeficient nu/nu Balb/c mice aged 10–12 weeks | Oral administration in feeding water; 240 mg/L | Reduced number of apoptosis and atretic follicles |
Hemadi, 2012 [19] | Balb/c mice | Heterologous thawed graft; donor: mice aged 10 days; recipient: 180 mice aged 8–10 weeks; 900 transplants | Oral administration; 20–200 mg/kg/day | Enhanced follicle quality, quantity, and graft size with low dosage; diminished Th1/Th2 immunological reaction and longer graft lifespan with high dosage |
Hemadi, 2011 [18] | F1 hybrid mice | Heterologous thawed graft; donor: mice aged 10 days; recipient: 60 mice aged 8–10 weeks | Graft: 100 μM PBF Recipient: intraperitoneal for 2 days; 20 mg/kg/day | Enhanced corpora lutea, secondary and antral follicles |
Hemadi, 2009 [17] | F1 hybrid mice | Heterologous thawed graft; donor: 120 mice aged 10 days; recipient: 36 mice aged 8–10 weeks | Graft: 100 μM PBF Recipient: intraperitoneal for 2 days; 20 mg/kg/day | Improved mean graft survival, ovary size, and revascularization |
Sapmaz, 2003 [14] | Wistar albino rats | Autologous fresh graft; 28 Wistar albino rats aged 12–14 weeks | intraperitoneal prior to transplantation; 20 mg/kg | Diminished ovarian and plasmatic malondialdehyde and ovarian necrosis; enhanced glutathione peroxidase and superoxide dismutase |